Daniel J. George, MD, of Duke University, discusses findings from a multicenter study of black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).
Manisha H. Shah, MD, of The Ohio State University Comprehensive Cancer Center, summarizes a session she chaired on progress in tailored treatments for medullary and anaplastic thyroid cancers as well as salivary gland cancer.
Gianni Bisogno, MD, of the University Hospital of Padova, discusses study findings on maintenance low-dose chemotherapy in patients with high-risk rhabdomyosarcoma (Abstract LBA2).
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss the implications of this study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).
Thaddeus Mason Pope, JD, PhD, of the Mitchell Hamline School of Law, discusses implications of the federal “Right to Try” law, recently enacted.
Jed A. Katzel, MD, of Kaiser Permanente, discusses his team’s findings on the disparities in head and neck cancer treatment for women and the possible missed opportunities to take a more aggressive and beneficial approach (Abstract LBA6002).
